Abstract:The glioblastoma multiforme (GBM) is one of the deadliest tumors. It has been speculated that virus plays a role in GBM but the evidences are controversy. Published researches are mainly limited to studies on the presence of human cytomegalovirus (HCMV) in GBM. No comprehensive assessment of the brain virome, the collection of viral material in the brain, based on recently sequenced data has been performed. Here, we characterized the virome from 111 GBM samples and 57 normal brain samples from eight projects i… Show more
“…Taking all of the controversies into account, a recent systematic review of 81 studies recruiting 7024 GB samples and 2420 blood samples revealed that HCMV is expressed in 36% and 45.2% of samples, respectively ( 108 ). Importantly, none of the healthy surrounding brain tissues employed as a control counterpart were detected to express HCMV genes or their products, indicating a high level of protection against off-tumor cytotoxicity for potential CMV-based immunotherapeutics for GB patients ( 72 , 109 – 112 ).…”
A high percentage of malignant gliomas are infected by human cytomegalovirus (HCMV), and the endogenous expression of HCMV genes and their products are found in these tumors. HCMV antigen expression and its implications in gliomagenesis have emerged as a promising target for adoptive cellular immunotherapy (ACT) strategies in glioblastoma multiforme (GB) patients. Since antigen-specific T cells in the tumor microenvironments lack efficient anti-tumor immune response due to the immunosuppressive nature of glioblastoma, CMV-specific ACT relies on in vitro expansion of CMV-specific CD8+ T cells employing immunodominant HCMV antigens. Given the fact that several hurdles remain to be conquered, recent clinical trials have outlined the feasibility of CMV-specific ACT prior to tumor recurrence with minimal adverse effects and a substantial improvement in median overall survival and progression-free survival. This review discusses the role of HCMV in gliomagenesis, disease prognosis, and recent breakthroughs in harnessing HCMV-induced immunogenicity in the GB tumor microenvironment to develop effective CMV-specific ACT.
“…Taking all of the controversies into account, a recent systematic review of 81 studies recruiting 7024 GB samples and 2420 blood samples revealed that HCMV is expressed in 36% and 45.2% of samples, respectively ( 108 ). Importantly, none of the healthy surrounding brain tissues employed as a control counterpart were detected to express HCMV genes or their products, indicating a high level of protection against off-tumor cytotoxicity for potential CMV-based immunotherapeutics for GB patients ( 72 , 109 – 112 ).…”
A high percentage of malignant gliomas are infected by human cytomegalovirus (HCMV), and the endogenous expression of HCMV genes and their products are found in these tumors. HCMV antigen expression and its implications in gliomagenesis have emerged as a promising target for adoptive cellular immunotherapy (ACT) strategies in glioblastoma multiforme (GB) patients. Since antigen-specific T cells in the tumor microenvironments lack efficient anti-tumor immune response due to the immunosuppressive nature of glioblastoma, CMV-specific ACT relies on in vitro expansion of CMV-specific CD8+ T cells employing immunodominant HCMV antigens. Given the fact that several hurdles remain to be conquered, recent clinical trials have outlined the feasibility of CMV-specific ACT prior to tumor recurrence with minimal adverse effects and a substantial improvement in median overall survival and progression-free survival. This review discusses the role of HCMV in gliomagenesis, disease prognosis, and recent breakthroughs in harnessing HCMV-induced immunogenicity in the GB tumor microenvironment to develop effective CMV-specific ACT.
“…In 7 studies, NGS was used to detect the HCMV in 681 tumors. DNA was sequenced in two of these studies [71,94]; RNA was sequenced in four [77,91,93,97]; and one was a metagenomic analysis [72]. None of these studies found evidence of HCMV nucleic acids (Table 7).…”
Section: Detection Of the Hcmv Genome By Next-generation Sequencingmentioning
confidence: 99%
“…ISH was used in 15 studies of 339 tumor samples that included 18 analyses[2,36,44,50,52,54,56,61,63,66,76,78,87,95,96]. NGS was conducted in 681 tumor samples in 7 studies[71,72,77,91,93,94,97].…”
Glioblastoma is a malignant brain tumor with a dismal prognosis. The standard treatment has not changed in the past 15 years as clinical trials of new treatment protocols have failed. A high prevalence of the human cytomegalovirus (HCMV) in glioblastomas was first reported in 2002. The virus was found only in the tumor and not in the surrounding healthy brain tissue. Many groups have confirmed the presence of the HCMV in glioblastomas, but others could not. To resolve this discrepancy, we systematically reviewed 645 articles identified in different databases. Of these, 81 studies included results from 247 analyses of 9444 clinical samples (7024 tumor samples and 2420 blood samples) by different techniques, and 81 articles included 191 studies that identified the HCMV in 2529 tumor samples (36% of all tumor samples). HCMV proteins were often detected, whereas HCMV nucleic acids were not reliably detected by PCR methods. Optimized immunohistochemical techniques identified the virus in 1391 (84,2%) of 1653 samples. These data suggest that the HCMV is highly prevalent in glioblastomas and that optimized immunohistochemistry techniques are required to detect it.
“…Recently, researchers aimed to detect CMV in 36 infantile brain tumors other than glioblastoma multiforme, and viral DNA was not detected in any of these tumors [ 27 ]. Furthermore, comprehensive assessment of the brain virome in 111 GBM tumors revealed the absence of CMV [ 28 ]. It was stated that the reason for the conflicting findings lies in the lack of sensitivity in the methods used by the different research groups.…”
Section: Herpesviruses As Potent Causative Agents In Brain Tumorsmentioning
The role of certain viruses in malignant brain tumor development remains controversial. Experimental data demonstrate that human herpesviruses (HHVs), particularly cytomegalovirus (CMV), Epstein–Barr virus (EBV) and human herpes virus 6 (HHV-6), are implicated in brain tumor pathology, although their direct role has not yet been proven. CMV is present in most gliomas and medulloblastomas and is known to facilitate oncomodulation and/or immunomodulation, thus promoting cancer cell proliferation, invasion, apoptosis, angiogenesis, and immunosuppression. EBV and HHV-6 have also been detected in brain tumors and high-grade gliomas, showing high rates of expression and an inflammatory potential. On the other hand, due to the neurotropic nature of HHVs, novel studies have highlighted the engagement of such viruses in the development of new immunotherapeutic approaches in the context of oncolytic viral treatment and vaccine-based strategies against brain tumors. This review provides a comprehensive evaluation of recent scientific data concerning the emerging dual role of HHVs in malignant brain pathology, either as potential causative agents or as immunotherapeutic tools in the fight against these devastating diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.